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Introduction: Accurate assessment of lymph node (LN) involvement 
with malignancy is critical to staging and management of non–small-
cell lung cancer. The goal of this retrospective study was to deter-
mine the tumor and imaging characteristics independently associated 
with malignant involvement of LNs visualized on positron emission 
tomography/computed tomography (PET/CT).
Methods: From 2002 to 2011, 172 patients with newly diagnosed non–
small-cell lung cancer underwent PET/CT within 31 days before LN 
biopsy. Among these patients, 504 anatomically defined, pathology-
confirmed LNs were visualized on PET/CT. Logistic regression analy-
sis was used to determine the associations between nodal involvement 
with malignancy and several clinical and imaging variables, including 
tumor histology, tumor grade, LN risk category in relation to the pri-
mary tumor location, pathologic findings from additional biopsied LNs, 
interval between PET/CT and biopsy, primary tumor largest dimension, 
primary tumor standardized uptake value (SUV
max
), LN short-axis 
dimension, and LN SUV
max
.
Results: On univariate analysis, adenocarcinoma histology 
(p = 0.010), high LN risk category (p < 0.001), larger LN short-axis 
dimension (p < 0.001), and higher LN SUV
max
 (p < 0.001) all cor-
related with nodal involvement. On multivariate analysis, adenocar-
cinoma histology (p = 0.003), high LN risk category (p = 0.005), and 
higher LN SUV
max
 (p < 0.001) correlated with nodal involvement, 
whereas LN short-axis dimension was no longer statistically signif-
icant (p = 0.180). A nomogram developed for clinical application 
based on this analysis had excellent concordance between predicted 
and observed results (concordance index, 0.95).
Conclusion: Adenocarcinoma histology, higher LN SUV
max
, and 
higher LN risk category independently correlate with nodal involve-
ment with malignancy and may be used in a model to accurately pre-
dict the risk of a node’s involvement with malignancy.
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(J Thorac Oncol. 2015;10: 1207–1212)
Lymph node (LN) staging is an important component of the workup of patients with non–small-cell lung cancer 
(NSCLC), as it affects prognosis and guides management.1 
Although 18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT) is the most 
accurate imaging modality for LN staging, it is still not con-
sidered accurate enough to forego pathologic confirmation of 
nodal involvement with malignancy.2 Common procedures for 
obtaining LN pathology such as mediastinoscopy and endo-
bronchial ultrasound-guided biopsies are limited, although, in 
terms of the stations of nodes that can be accessed in a single 
procedure, and as such, improving the accuracy of imaging 
techniques is also crucial in guiding the surgical approach. 
Moreover, for the many patients with NSCLC who are medi-
cally inoperable with significant comorbidities that limit the 
feasibility of safely performing an invasive procedure because 
of the risk of complications, improving noninvasive, imag-
ing-based approaches to predict the nodal involvement with 
malignancy would expedite definitive management of their 
disease and improve radiation therapy target volume delinea-
tion, potentially sparing patients from the toxicity associated 
with a larger treatment volume while enabling treatment of 
gross disease to high doses.3–5
Multiple studies have attempted to predict nodal involve-
ment with malignancy based on a variety of size and/or SUV 
criteria using imaging modalities such as CT, PET, or PET/CT. 
These studies generally can be divided into those assessing 
individual nodes based strictly on the imaging characteristics 
of that node and those assessing the risk to a more global LN 
region based on the types of primary tumor-specific factors, 
for instance determining the incidence of occult mediastinal 
LN positivity in patients with a clinically negative mediasti-
num on PET and/or CT. Regarding the former, the reported 
ranges for sensitivity and specificity for individual LNs based 
on the size or SUV criteria are wide, because the studies were 
performed in different patient populations and used different 
criteria for malignancy to increase either the sensitivity or the 
specificity of the imaging test.6–14 Regarding the latter, there 
are conflicting data on which factors are most important in 
predicting mediastinal spread, depending on a multitude of 
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factors including the type of imaging used, surgical techniques, 
and how one defines nodal positivity on imaging alone.15–24 In 
this study, we sought to synthesize these concepts to deter-
mine which tumor and imaging characteristics are indepen-
dently associated with involvement of specific pathologically 
confirmed LNs to develop a more accurate predictive tool to 
improve noninvasive nodal evaluation in NSCLC.
PATIENTS AND METHODS
This study retrospectively assessed 504 LNs from 172 
patients, which were both biopsied and visualized on a pre-
biopsy PET/CT. Patients were identified for inclusion from 
the charts of 729 consecutive patients with newly diagnosed 
NSCLC who underwent pathologic LN staging at Memorial 
Sloan-Kettering Cancer Center (MSKCC) from 2002 to 2011 
and PET/CT within 31 days before biopsy. Only LNs that 
were anatomically defined at the time of biopsy according to 
their LN station were included in this analysis, because this 
information was used to identify the biopsied node on PET/
CT. Any biopsied LNs for which no visible LN could be iden-
tified in the station of interest on PET/CT were excluded. 
Conversely, if more than one LN could be visualized in a sta-
tion of interest, the imaging characteristics of the largest LN 
in that region were recorded.
Patients with a history of previous chemotherapy, 
radiation therapy, granulomatous disease, or nonskin can-
cer malignancy were excluded. Nodal pathology could be 
obtained by any means, including excisional biopsy (by 
means of mediastinoscopy, thoracotomy, etc.) or minimally 
invasive biopsy/needle aspiration (by means of bronchos-
copy, endobronchial ultrasound, etc.). The selection of LNs 
to biopsy was at the discretion of the clinician performing 
the biopsy, but it was not restricted to LNs that appeared 
malignant on imaging, because many LN stations were biop-
sied as part of the clinician’s standard staging evaluation of 
the patient. Given the retrospective nature of this study, no 
further information was readily available to explain the ratio-
nale for each individual biopsy.
The PET/CT scans were carried out on a variety of scan-
ner models, both within our institution and at outside hospi-
tals or imaging centers. More than 15 scanner types/models 
were used among the patients included in this study. For the 
patients who underwent PET/CT at MSKCC, patient prepara-
tion and image acquisition protocols were comparable over 
the years. Patients were instructed to fast for at least 6 hours 
before FDG administration, and blood glucose levels were 
required to be less than 200 mg/dl at the time of injection. The 
scans were acquired from the upper thighs to the base of the 
skull (5–7 bed positions) 60 to 90 minutes after injection of 
approximately 400 MBq FDG. CT was performed for attenua-
tion correction and anatomical localization. Immediately after 
the CT image acquisition, PET data were acquired for 3 to 5 
minutes per bed position. The attenuation-corrected PET data 
were reconstructed using an ordered-subset expectation maxi-
mization iterative reconstruction. All raw Digital Imaging and 
Communications in Medicine files from scans at our center 
and outside institutions were imported into the AW Volume 
Viewer software (GE Healthcare, Pittsburgh, PA) without 
adjustments for differing scanner and protocol methods. All 
images were re-reviewed for the purpose of this study using 
the AW Volume Viewer software to verify and remeasure the 
results initially reported by a board-certified nuclear medicine 
radiologist. Parameters that were remeasured included the 
primary tumor largest dimension, primary tumor SUV
max
, LN 
short-axis dimension, and LN SUV
max
. SUV
max
 was defined as 
the highest FDG uptake within a region of interest that encom-
passed a given lesion, as defined according to PET response 
criteria in solid tumors (PERCIST) criteria.25
Univariate logistic regression analysis was used to 
determine whether there was an association between nodal 
involvement with malignancy and several clinical and imag-
ing variables, including tumor histology, tumor grade, LN 
risk category (as defined in Table 1), pathologic findings from 
any additional biopsied LNs, interval between PET/CT and 
biopsy, PET/CT location, primary tumor largest dimension, 
primary tumor SUV
max
, LN short-axis dimension, and LN 
SUV
max
. Of note, LN risk categories based on the primary 
tumor location were based on the patterns of nodal spread 
as described in previous surgical series.16,26–29 Factors with a 
p value less than 0.05 on univariate analysis were included 
in the multivariate logistic regression model. A nomogram 
for predicting LN involvement with malignancy based on the 
aforementioned multivariate analysis was developed for clin-
ical application. Concordance index (c-index) was calculated 
for the multivariate model, which was used to estimate the 
probability of concordance between predicted and observed 
responses. The c-index ranges from 0.5 to 1.0, with a value of 
0.5 indicating that the model is no better than chance, and a 
value of 1.0 indicating perfect discrimination. Internal cross-
validation of the predictive model was performed using the 
Jackknife (leave-one-out) method, with Hosmer–Lemeshow 
goodness-of-fit statistic computed to examine the calibra-
tion of the model. Statistical analysis was performed using 
the software SAS version 9.2 (SAS Institute, Inc. Cary, NC). 
This study was approved by the MSKCC institutional review 
board (WA0099-13) and was performed following the ethical 
principles of the Declaration of Helsinki.
RESULTS
The median age of the 172 patients who met our criteria 
for analysis was 67.1 years (range, 43.6–97.3 years), and 90% 
were either current or former smokers. The characteristics of 
their primary tumors are shown in Table 2. The median pri-
mary tumor size in the single largest dimension was 2.8 cm 
TABLE 1.  Definition of Lymph Node Risk Categories
High Intermediate Low
RUL 10–14R, 4R 1R, 2R, 3, 7, 8, 9 1L, 2L, 4L, 5, 6, 10L
RML 10–14R, 4R, 7 1R, 2R, 3, 8, 9 1L, 2L, 4L, 5, 6, 10L
RLL 10–14R, 4R, 7 1R, 2R, 3, 8, 9 1L, 2L, 4L, 5, 6, 10L
LUL 10–14L, 4L, 5, 6 1L, 2L, 3, 7, 8, 9 1R, 2R, 4R, 10R
LLL 10–14L, 4L, 7 1L, 2L, 3, 5, 6, 8, 9 1R, 2R, 4R, 10R
LLL, left lower lobe; LUL, left upper lobe; RML, right middle lobe; RLL, right 
lower lobe; RUL, right upper lobe.
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(range, 0.4–12.0 cm), and the median primary tumor SUV
max
 
was 10.5 (range, 0.4–44.4).
The mean interval between PET/CT and LN biopsy 
was 15.8 days (standard deviation, 8.5 days). The PET/CT 
was performed at our institution in 77% of patients and at an 
outside institution in 23% of patients. The characteristics of 
the 504 evaluated LNs are shown in Table 3. The median LN 
short-axis size was 0.7 cm (range, 0.3–4.7 cm), and the median 
SUV
max
 was 2.1 (range, 0.5–20.3). Among the pathologically 
positive nodes (n = 68), the median SUV
max
 was 6.2 (range, 
1.5–20.3), and eight nodes (11.8%) had SUV
max
 less than 3.0.
According to the univariate analysis in Table 4, adeno-
carcinoma (versus squamous cell) histology, high (versus low 
to intermediate) LN risk category, larger LN short-axis dimen-
sion, higher LN SUV
max
, and PET/CT scan from an outside 
institution all correlated with a higher odds ratio for nodal 
involvement with malignancy. Factors that failed to demon-
strate significant association on univariate analysis included 
tumor grade, interval between PET/CT and biopsy, primary 
tumor size, and primary tumor SUV
max
. According to the 
multivariate analysis, adenocarcinoma histology, high LN 
risk category, higher LN SUV
max
, and PET/CT scan from an 
outside institution all correlated with a higher odds ratio for 
nodal involvement with malignancy, whereas the association 
with LN short-axis dimension was no longer statistically sig-
nificant. Of note, the location of PET/CT was not included in 
the final model (Table 5), because it has no clinical relevance to 
patients and physicians not limited to our center. Its inclusion 
only marginally increased the c-index from 0.950 to 0.955. 
A nomogram for predicting LN involvement with malignancy 
based on the results of the multivariate analysis is shown in 
Figure 1. The c-index for the multivariate model was 0.95. 
A calibration curve validating model performance is shown in 
Figure 2. The Hosmer–Lemeshow goodness-of-fit test showed 
no significant difference between observed and expected nodal 
involvement with malignancy ( p = 0.68). The c-index of the 
validation model was 0.87, indicating good discrimination.
DISCUSSION
In this study, we have shown that a combination of 
clinical and imaging characteristics can be used to accurately 
predict nodal involvement with malignancy in patients with 
newly diagnosed NSCLC. Adenocarcinoma histology, higher 
LN SUV
max
, and higher LN risk category in relation to the pri-
mary tumor site were all independently associated with nodal 
positivity. Given the large number of nodes assessed in this 
study, the final model may serve as a powerful tool in guid-
ing the approach to pathologic nodal staging and improving 
noninvasive assessment in those patients receiving nonsurgi-
cal management of their disease.
Several previous studies have explored predictive mod-
els for nodal involvement in NSCLC, primarily in the con-
text of determining the risk factors for any mediastinal LN 
involvement with malignancy in patients with a clinically neg-
ative mediastinum on PET or CT.15–24 This should be distin-
guished from our approach, in which specific LNs visible on 
imaging were assessed for the probability of their involvement 
with malignancy, with the goal being more accurate classifica-
tion of nodes that are otherwise challenging to interpret based 
on the commonly used PET or CT criteria alone. With this 
distinction in mind, it is not surprising that characteristics of 
the primary tumor such as size and SUV
max
, which have been 
demonstrated to predict for a higher global risk of LN involve-
ment in previous studies, were not as predictive of involve-
ment of specific LNs as the qualities of that LN itself in our 
study. The ability of SUV
max
 of the primary tumor to predict 
for occult nodal involvement with malignancy is controversial 
TABLE 2.  Primary Tumor Characteristics
Characteristic n (%)
Tumor histology
  Adenocarcinoma 104 (59)
  Squamous cell carcinoma 54 (31)
  Other/unclassified 14 (8)
Tumor location
  Right upper lobe 68 (39)
  Right middle lobe 9 (5)
  Right lower lobe 34 (20)
  Left upper lobe 36 (21)
  Left lower lobe 25 (15)
Tumor grade
  Well differentiated 4 (2)
  Moderately differentiated 65 (38)
  Poorly differentiated 93 (54)
  Unknown 10 (6)
TABLE 3.  Lymph Node Characteristics
Characteristic n (%)
Lymph node station
  Station 1–3 12 (2)
  Station 4 224 (44)
  Station 5–6 22 (4)
  Station 7 131 (26)
  Station 8–9 29 (6)
  Station 10–14 86 (17)
Means of obtaining pathology
  Excision by thoracotomy 112 (22)
  Excision by mediastinoscopy 355 (70)
  Fine-needle aspiration 37 (7)
Lymph node histology
  Benign 436 (86)
  Malignant 68 (14)
Additional biopsied lymph node(s)
  Negative 376 (75)
  >1 positive 95 (19)
  Unknown 33 (7)
LN risk category
  High 227 (45)
  Intermediate 171 (34)
  Low 106 (21)
LN, lymph node.
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in itself, because two recent studies from large academic cen-
ters have conflicting findings.15,24 Given that SUV is a func-
tion of tumor size and histology, this inconsistency may stem 
from variability in the patient populations evaluated in dif-
ferent studies. Trister et al. also did not include the primary 
tumor size as an independent variable during analysis, which 
limits its interpretability. However, our findings do agree with 
the majority of the published literature in implicating adeno-
carcinoma histology as a risk factor for LN involvement with 
malignancy.16–18
Primary tumor location has often been associated with 
the risk of LN involvement with malignancy, although the 
highest risk location was the upper lobes in some studies,17,18 
the upper or middle lobes in another study,16 and central loca-
tion irrespective of lobe in other studies.18,21,23 Given that our 
study evaluated specific nodal stations rather than the risk 
for any mediastinal involvement, we took a slightly different 
approach, defining the LN risk categories based on the known 
patterns of occult nodal spread16,26–29 and found that this cat-
egorization was independently predictive of the presence of 
metastasis in a given LN in question.
Somewhat unexpectedly, LN short-axis dimension 
was not associated with nodal involvement with malignancy 
on multivariate analysis. Although the reason for this is not 
entirely clear, it may be due to strong associations between LN 
short-axis dimension and other factors that were included in 
the model, such as LN risk category and SUV
max
. It could also 
be related to the fact that most of the LNs evaluated in this 
study were pathologically benign, and as such the median LN 
short-axis dimension was relatively small. With less measured 
variability in LN size, the multivariate model may not have 
been adequately powered to detect a difference. Although LN 
short-axis dimension made negligible impact on the predictive 
power of the nomogram, we elected to include it in the final 
prediction model because clinically LN size has been consis-
tently used in predicting the risk of nodal malignancy in the 
pre-PET era, albeit as a relatively unreliable parameter.6
Finally, there is conflicting evidence for whether clini-
cally positive hilar LNs on PET is a risk factor for mediastinal 
involvement.15–18 In a recent large series, Farjah et al.15 actually 
found that for patients with clinical stage T1-2 N0-1 NSCLC 
by PET/CT, only clinically positive hilar nodal involvement 
was correlated with pathologic mediastinal LN involvement, 
whereas primary tumor location, size, histology, and SUV
max
, 
and extent of nodal disease on CT were not associated with 
pathologic mediastinal LN involvement. Similarly, Dooms 
et al.30 also recently reported that 24% of patients who were 
clinically N1 based on the PET harbored pathologic medias-
tinal LN malignancy. Interestingly, our model did not show 
that the pathologic status of additional biopsied LNs (hilar 
or mediastinal) correlated with the status of a node in ques-
tion. This discrepancy may be because we strictly included 
only pathologic information in this analysis so as to avoid any 
uncertainty associated with interpretation of hilar LN involve-
ment based on the imaging alone or because these previous 
publications inconsistently report the criteria for clinically 
defining hilar nodal involvement on PET or CT, or the elapsed 
time from imaging to pathologic assessment, all of which 
would impact the outcome of the study.
There are several important limitations to this study. 
First, we relied on accurate documentation of nodal station 
on the biopsy report to identify and correlate the pathologic 
findings with the imaging findings, an approach which will 
inevitably lead to some misclassification, perhaps more so for 
TABLE 4.  Univariate Logistic Regression Analysis of the 
Relationship between Clinical Characteristics and PET 
Parameters with Nodal Involvement with Malignancy
Factor Odds Ratio (95% CI) p Value
Tumor histology
  Squamous cell 1.00 (reference)
  Adenocarcinoma 2.29 (1.20–4.34) 0.01
  Other 0.83 (0.23–3.06) 0.78
Tumor grade
  Well 0.29 (0.04–2.25) 0.24
  Moderate 0.78 (0.45–1.34) 0.36
  Poor 1.00 (reference)
  Not reported 0.70 (0.20–2.42) 0.57
Lymph node risk category
  High 1.00 (reference)
  Low to intermediate 0.15 (0.08–0.29) <0.01
Additional biopsied LN(s)
  Negative 1.00 (reference)
  Positive (≥1) 1.55 (0.78–3.05) 0.21
PET/CT location
  MSKCC 1.00 (reference)
  Outside institution 2.48 (1.45–4.25) <0.01
Interval from PET/CT to  
biopsy (days)
0.99 (0.96–1.02) 0.63
Primary tumor largest  
dimension (cm)
0.91 (0.79–1.04) 0.16
Primary tumor SUV
max
0.97 (0.94–1.01) 0.13
Lymph node short-axis  
dimension (cm)
17.52 (8.90–34.49) <0.01
Lymph node SUV
max
2.17 (1.82–2.58) <0.01
CI, confidence interval; CT, computed tomography; LN, lymph node; MSKCC, 
Memorial Sloan-Kettering Cancer Center; PET, positron emission tomography.
TABLE 5.  Multivariate Logistic Regression Analysis of 
the Relationship between Clinical Characteristics and PET 
Parameters with Nodal Involvement with Malignancy
Factor Odds Ratio (95% CI) p Value
Tumor histology
  Squamous cell 1.00 (reference)
  Adenocarcinoma 5.04 (1.76–14.48) <0.01
  Other 3.40 (0.46–25.45) 0.23
Lymph node risk category
  High 1.00 (reference)
  Low to intermediate 0.28 (0.12–0.68) <0.01
Lymph node SUV
max
2.00 (1.64–2.44) <0.01
Lymph node short-axis 
dimension (cm)
1.76 (0.77–3.99) 0.18
CI, confidence interval; PET, positron emission tomography.
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hilar than mediastinal nodal stations. We attempted to mini-
mize this by excluding any stations for which there was no 
clearly identifiable node and recording data for only the largest 
node in a given station with multiple visible nodes, because 
this would generally be the node most likely to be surgically 
or endoscopically accessible for biopsy. Another source of bias 
may lie in the nodes that were selected for biopsy, because 
some of these were biopsied based on the physician’s standard 
evaluation rather than any abnormality on CT or PET. Needle 
aspiration by endobronchial ultrasound-guided transbronchial 
lymph node aspiration was performed in a minority of patients 
in our study, but it is known to be associated with false- 
negative nodal pathology due to insufficient tissue sampling at 
a rate of approximately 10%.28 Finally, although the inclusion 
of outside scans in this study may be viewed as a limitation due 
to subtle variations in image acquisition and reconstruction 
procedures, we would argue that this may make our findings 
more generalizable. PET/CT location at an outside institution 
was associated with nodal positivity, but this is most likely 
related to other factors, for instance differences in the presen-
tation, workup, or management of patients, or referral bias for 
patients with more advanced disease. These limitations should 
be carefully weighed against the strengths of our data, which 
include the assessment of a larger number of LNs than most 
studies of this kind and the strict use of pathologic information 
rather than clinical nodal assessment to guide our analysis.
CONCLUSION
Adenocarcinoma histology, higher LN SUV
max
, and higher 
LN risk category independently correlate with nodal involve-
ment with malignancy and may be used in a model to accurately 
predict the risk of a node’s involvement with malignancy.
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